Jayson Bedford
Stock Analyst at Raymond James
(3.92)
# 593
Out of 4,876 analysts
312
Total ratings
55.93%
Success rate
7.48%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $328 → $360 | $309.83 | +16.19% | 27 | May 27, 2025 | |
| ICUI ICU Medical | Maintains: Strong Buy | $197 → $187 | $130.68 | +43.10% | 20 | May 9, 2025 | |
| MASI Masimo | Maintains: Outperform | $204 → $185 | $166.71 | +10.97% | 7 | May 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $119 → $104 | $91.74 | +13.36% | 8 | May 6, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $116 → $108 | $92.80 | +16.38% | 27 | Apr 25, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $122 → $121 | $104.58 | +15.70% | 25 | Apr 24, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $142 | $133.67 | +6.23% | 28 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $162 → $164 | $152.01 | +7.89% | 23 | Apr 16, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $534.19 | +28.79% | 8 | Jan 24, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $85.04 | +16.42% | 30 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $169.97 | +58.85% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.46 | +24.28% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $9.87 | +1.32% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $119.58 | +126.63% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.10 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.11 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $77.15 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.50 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $86.18 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.50 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $65.11 | +32.08% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.39 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.21 | - | 3 | Jan 2, 2018 |
Insulet
May 27, 2025
Maintains: Outperform
Price Target: $328 → $360
Current: $309.83
Upside: +16.19%
ICU Medical
May 9, 2025
Maintains: Strong Buy
Price Target: $197 → $187
Current: $130.68
Upside: +43.10%
Masimo
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $166.71
Upside: +10.97%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $119 → $104
Current: $91.74
Upside: +13.36%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $116 → $108
Current: $92.80
Upside: +16.38%
Boston Scientific
Apr 24, 2025
Maintains: Strong Buy
Price Target: $122 → $121
Current: $104.58
Upside: +15.70%
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $133.67
Upside: +6.23%
Johnson & Johnson
Apr 16, 2025
Maintains: Outperform
Price Target: $162 → $164
Current: $152.01
Upside: +7.89%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $534.19
Upside: +28.79%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $85.04
Upside: +16.42%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $169.97
Upside: +58.85%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $10.46
Upside: +24.28%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $9.87
Upside: +1.32%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $119.58
Upside: +126.63%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.10
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $19.11
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $77.15
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.50
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $86.18
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.50
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $65.11
Upside: +32.08%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.39
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $12.21
Upside: -